GLENN L. COOPER - Corporate Board Profile

REPLIGEN CORP

Filing Date	Source Excerpt
2012-04-20	The following table sets forth a summary of the compensation the Company paid to its non-employee directors in the nine months ended December 31, 2011. The following table sets forth a summary of the compensation the Company paid to its non-employee directors in the nine months ended December 31, 2011. Glenn L. Cooper 33,250 25,196 58,446
2013-04-09	Glenn L. Cooper, M.D. has served as a Director of Repligen since August 2009. ... Mr. Cooper's qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies and his expertise in the clinical and regulatory areas. ... The Audit Committee currently consists of Mr. Ryan, Ms. Dawes and Mr. Cooper. ... The Compensation Committee, of which Mr. Cooper, Mr. Griffith and Mr. Henry are currently members, ... Mr. Cooper serves as the Chairperson of the Compensation Committee. ... Director Compensation Table for the Fiscal Year Ended December 31, 2012: Glenn L. Cooper: Fees Earned or Paid in Cash $61,000, Stock Awards $50,002, Total $111,002.
2014-04-08	Glenn L. Cooper (1)(2) 61 Director; Member of the Compensation Committee; Member of the Audit Committee; Director Compensation Table for the Fiscal Year Ended December 31, 2013: Glenn L. Cooper Fees Earned or Paid in Cash $59,000, Stock Awards $50,001, Total $109,001.
2015-04-17	Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. ... Dr. Cooper's qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies. ... The Audit Committee was established in accordance with section 3(a)(58)(A) of the Exchange Act and currently consists of Messrs. Ryan and Cox and Dr. Cooper. ... The Audit Committee met four times during the fiscal year ended December 31, 2014. Mr. Ryan currently serves as Chairperson of the Audit Committee. ... The Compensation Committee, of which Dr. Cooper, Mr. Griffith and Mr. Barthelemy (who replaced Dr. Goldberg on the Compensation Committee in December 2014) are currently members ... Director Compensation Table for the Fiscal Year Ended December 31, 2014 ... Glenn L. Cooper 58,500 Fees Earned or Paid in Cash ($) 35,008 Stock Awards ($) 34,958 Option Awards ($) Total 128,466
2016-04-11	Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. ... Dr. Cooper's qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies. ... The Compensation Committee, of which Dr. Cooper, Mr. Barthelemy and Mr. Muir (effective as of October 2015) are currently members ... Director Compensation Table for the Fiscal Year Ended December 31, 2015 ... Glenn L. Cooper Fees Earned or Paid in Cash($) 68,665, Stock Awards($) 41,973, Option Awards($) 44,807, Total($) 155,445.
2017-04-21	Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. ... Dr. Cooper's qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies. ... The Audit Committee currently consists of Mr. Muir, Chairperson, Mr. Cox and Mr. Ryan. ... The Compensation Committee, of which Dr. Cooper, Mr. Barthelemy and Mr. Muir are currently members ... Director Compensation Table for the Fiscal Year Ended December 31, 2016 ... Glenn L. Cooper 61,000 46,050 46,476 153,526
2018-04-20	Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. Dr. Cooper served as Executive Chairman of Coronado BioSciences, Inc. from 2010 to 2012. ... Dr. Cooper has participated in the development, approval and commercialization of numerous drugs including Prozac®, Axid®, Lorabid®, Ceclor®, SANCTURA®, SANCTURA XR®, Supprelin-LA® and Vantas®. ... Dr. Cooper's qualifications to sit on the Board of Directors of the Company include his leadership roles at pharmaceutical companies.
2019-04-18	Glenn L. Cooper, M.D. has served as a director of Repligen since August 2009. ... Dr. Cooper has participated in the development, approval and commercialization of numerous drugs. ... Dr. Cooper serves as the Chairperson of the Compensation Committee. ... Director Compensation Table for the Fiscal Year Ended December 31, 2018: Glenn L. Cooper Total Compensation: $195,370.